Macquarie Group
ALBO

Macquarie Group’s Albireo Pharma Inc ALBO Stock Holding History

Macquarie Group’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-405
Closed -$8.38K – 2396
2022
Q2 		$8K Hold
405
– – ﹤0.01% 2483
2022
Q1 		$12 Hold
405
– – ﹤0.01% 2499
2021
Q4 		$9K Hold
405
– – ﹤0.01% 2529
2021
Q3 		$13K Hold
405
– – ﹤0.01% 2520
2021
Q2 		$14K Hold
405
– – ﹤0.01% 2438
2021
Q1 		$14K Buy
+405
New +$15K ﹤0.01% 2353
2018
Q1 		– Sell
-300
Closed -$8K – 2439
2017
Q4 		$8K Buy
+300
New +$7.61K ﹤0.01% 2322

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Macquarie Group's ALBO Position: Q3 2022 in Review

Macquarie Group sold out of Albireo Pharma Inc (ALBO) in Q3 2022, closing a stake of 405 shares — an estimated $8.38K sold.

Macquarie Group first reported a position in ALBO in Q4 2017 and held it in 7 quarters. The position peaked at $14K in Q2 2021. 108 funds tracked by Wall St. Rank hold ALBO as of Q3 2022.

  • Macquarie Group reported no remaining Albireo Pharma Inc position as of Q3 2022 after selling out during the quarter.
  • Macquarie Group sold 405 Albireo Pharma Inc shares in Q3 2022, an estimated $8.38K.
  • Macquarie Group first reported a position in Albireo Pharma Inc in Q4 2017 and held it in 7 quarters.
  • Macquarie Group's Albireo Pharma Inc position peaked at $14K in Q2 2021.
  • 108 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.